WO2014119985A3 - Pharmaceutical composition comprising a selective phosphodiesterase enzyme inhibitor in oral gel form - Google Patents

Pharmaceutical composition comprising a selective phosphodiesterase enzyme inhibitor in oral gel form Download PDF

Info

Publication number
WO2014119985A3
WO2014119985A3 PCT/MX2014/000028 MX2014000028W WO2014119985A3 WO 2014119985 A3 WO2014119985 A3 WO 2014119985A3 MX 2014000028 W MX2014000028 W MX 2014000028W WO 2014119985 A3 WO2014119985 A3 WO 2014119985A3
Authority
WO
WIPO (PCT)
Prior art keywords
selective phosphodiesterase
phosphodiesterase enzyme
enzyme inhibitor
pharmaceutical composition
gel form
Prior art date
Application number
PCT/MX2014/000028
Other languages
Spanish (es)
French (fr)
Other versions
WO2014119985A2 (en
Inventor
Miguel Ángel GARCIA PÉREZ
Gabriel MARCELÍN JIMÉNEZ
Concepción Albina VÁZQUEZ FLORES
Ricardo David ÁVILA CEDILLO
Alionka Citlalli P. ANGELES MORENO
Octavio CARO RODRÍGUEZ
Original Assignee
Garcia Pérez Miguel Ángel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garcia Pérez Miguel Ángel filed Critical Garcia Pérez Miguel Ángel
Publication of WO2014119985A2 publication Critical patent/WO2014119985A2/en
Publication of WO2014119985A3 publication Critical patent/WO2014119985A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Abstract

The invention concerns a novel stable, semi-solid composition for oral administration comprising at least one selective phosphodiesterase enzyme inhibitor and/or at least one pharmaceutically acceptable excipient. Once administered orally, the composition maintains sustained release, doubling the length of time for which the active ingredient remains in the organism and prolonging the therapeutic effect of the selective phosphodiesterase enzyme inhibitor. The semi-solid composition can be used for selective phosphodiesterase enzyme inhibition, for example, in a non-restrictive manner, for controlling or treating erectile dysfunction, with a therapeutic effect lasting for up to eight hours.
PCT/MX2014/000028 2013-01-31 2014-01-28 Pharmaceutical composition comprising a selective phosphodiesterase enzyme inhibitor in oral gel form WO2014119985A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2013/001279 2013-01-31
MX2013001279A MX2013001279A (en) 2013-01-31 2013-01-31 Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.

Publications (2)

Publication Number Publication Date
WO2014119985A2 WO2014119985A2 (en) 2014-08-07
WO2014119985A3 true WO2014119985A3 (en) 2014-11-27

Family

ID=49552933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000028 WO2014119985A2 (en) 2013-01-31 2014-01-28 Pharmaceutical composition comprising a selective phosphodiesterase enzyme inhibitor in oral gel form

Country Status (2)

Country Link
MX (1) MX2013001279A (en)
WO (1) WO2014119985A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584248B1 (en) * 2015-03-24 2017-04-19 Farmalider, S.A. Pharmaceutical composition of sildenafil citrate in suspension form for oral use
RU2649834C1 (en) * 2016-07-06 2018-04-04 Фармалидер С.А. Pharmaceutical composition of sildenafil citrate in form of suspension for oral administration
CN112587476B (en) * 2020-12-23 2022-09-27 无锡市妇幼保健院 Novel sildenafil gel formulation suitable for neonatal arterial hypertension and preparation method thereof
CN113577079B (en) * 2021-07-28 2022-08-23 山东裕欣药业有限公司 Preparation method and composition of phosphodiesterase inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060353A1 (en) * 2000-02-21 2001-08-23 Fujisawa Pharmaceutical Co., Ltd. Liquid preparation with improved absorbability
JP2010241798A (en) * 2009-03-18 2010-10-28 Daiichi Sankyo Healthcare Co Ltd Sildenafil citrate-containing oral liquid formulation and vessel containing the liquid formulation
DE102009033396A1 (en) * 2009-07-16 2011-01-20 Ratiopharm Gmbh An aqueous solution and gelatinized composition comprising a phosphodiesterase 5 inhibitor and methods and use thereof
CN102204917A (en) * 2011-03-30 2011-10-05 天津红日药业股份有限公司 Pharmaceutical composition containing fasudil and sildenafil, and preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060353A1 (en) * 2000-02-21 2001-08-23 Fujisawa Pharmaceutical Co., Ltd. Liquid preparation with improved absorbability
JP2010241798A (en) * 2009-03-18 2010-10-28 Daiichi Sankyo Healthcare Co Ltd Sildenafil citrate-containing oral liquid formulation and vessel containing the liquid formulation
DE102009033396A1 (en) * 2009-07-16 2011-01-20 Ratiopharm Gmbh An aqueous solution and gelatinized composition comprising a phosphodiesterase 5 inhibitor and methods and use thereof
CN102204917A (en) * 2011-03-30 2011-10-05 天津红日药业股份有限公司 Pharmaceutical composition containing fasudil and sildenafil, and preparation method and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200171, Derwent World Patents Index; AN 2001-616113 *
DATABASE WPI Week 201076, Derwent World Patents Index; AN 2010-N63986 *
DATABASE WPI Week 201105, Derwent World Patents Index; AN 2011-N80718 *
DATABASE WPI Week 201113, Derwent World Patents Index; AN 2011-A90507, DW *

Also Published As

Publication number Publication date
WO2014119985A2 (en) 2014-08-07
MX2013001279A (en) 2013-08-26

Similar Documents

Publication Publication Date Title
MX2022006258A (en) Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2016013529A (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof.
MX361590B (en) Topical delivery of skin compositions having low ph.
CY1118057T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
NZ605469A (en) Nalbuphine-based formulations and uses thereof
TN2015000135A1 (en) Modified release formulations for oprozomib
MX347927B (en) Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease.
WO2014130691A3 (en) Pharmaceutical formulations of nitrite and uses thereof
WO2014119985A3 (en) Pharmaceutical composition comprising a selective phosphodiesterase enzyme inhibitor in oral gel form
JO3587B1 (en) Oral dosage forms of bendamustine
MX2015017879A (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase.
MX2021008536A (en) Modified release tablet formulations containing phosphodiesterase inhibitors.
NZ726132A (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022013450A (en) Pharmaceutical formulations.
MX2016016400A (en) Stabilized oxymetazoline formulations and their uses.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
WO2015166418A3 (en) Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient
GR1008819B (en) Pharmaceutical composition comprising atomoxetine and method for the preparation thereof
EA201200799A1 (en) HEPATATROPETECTED MEDICINE
MX352778B (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
MX2015009504A (en) Desloratadine-based pharmaceutical composition to be orally administered, for the treatment of histamine related diseases.
UA110792C2 (en) Pharmaceutical form bendamustine for oral use

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14745757

Country of ref document: EP

Kind code of ref document: A2